格列衛(wèi)與造血干細(xì)胞移植治療慢性粒細(xì)胞白血病的觀察.pdf

1、新疆醫(yī)科大學(xué)碩士學(xué)位論文格列衛(wèi)與造血干細(xì)胞移植治療慢性粒細(xì)胞白血病的觀察姓名：那仁花申請(qǐng)學(xué)位級(jí)別：碩士專業(yè)：內(nèi)科學(xué)指導(dǎo)教師：哈力達(dá)亞森200904新疆醫(yī)科大學(xué)醫(yī)學(xué)碩士學(xué)位論文新疆醫(yī)科大學(xué)醫(yī)學(xué)碩士學(xué)位論文—2—ObservationofPeopleTreatedwithGleevecAllogeneichematopoieticstemcelltransplantationinChronicMyelogenousLeukemiaPostg

2、raduate:NaRenHuaSupercison:Prof.HaLiDaYaSenAbstractObjective:Toobservetheimatinib(Gleevec)allogeneichematopoieticstemcelltransplantation(AlloSCT)inchronicmyelogenousleukemia(AML)inthetreatment.Methods:59casesatacleardiag

3、nosisofchronicmyeloidleukemiapatients39caseshaveacceptedtheAlloSCTtreatment20patientswithotheraltreatmentGleevec.ObservedseparatelyGleevecgroupstemcelltransplantationgroupsurvivalqualityoflifesituation.Survivalrateobserv

4、edduringtheperiodofcomparisonaswellasthesurvivalofthetwogroups.Results:Thehematopoieticstemcelltransplantationgroup3patientsdiedmtalityratewas7.69%(339)theleadingcauseofdeathfgraftversushostdisease(GVHD).Gleevecgrouprate

5、ofcompletehematologicremission(CHR)89.47%(1719)6monthrateofcompleteremission(CCR)31.58%(619)12monthsCCRrateof57.89%(1119).HavetwocasesofpatientstakingGleevecfdiseaseprogressionduringtheacutephasetheincidencerateof10.53%(

6、219).Observedduringtheperiodbetweenthesetwogroupsnosignificantdifferenceinsurvivalrates.Conclusions:GleevecgroupallogeneichematopoieticstemcellgroupcomparisonofsurvivalratesbetweenthetwogroupsnodifferenceGleevecbecauseof

7、expensivesoinourhospitalinpatientswithCMLcannotbealGleeveccaseifthereisasuitabledonallogeneichematopoieticstemcelltransplantationasfirstlinetreatmentcanstillbetakenintoaccount.Howeverfewcasesofthisstudywastoobservethetim

8、eisshtthefutureisstillneedffurtherfollowupstudy.Gleevecrequiredcontinuingmedicationexpensivethecostoftreatmentismuchlargerthanallogeneichematopoieticstemcelltransplantation.Keywds:chronicmyelogenousleukemia；Gleevec；allog